parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in breast secretory cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	24 Parkinson's papers of 2,059	0.58
pathways Reactome	2 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 6639

receipt 6646: PTN in dopamine neurons, braak

power: full sample +0.07 (p 0.774, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.820, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.10 (p 0.683, n 18). could be the mix.
skeptic: leave-one-out range -0.04 to +0.21, sign flips 2; without severely affected donors +0.07 (p 0.774, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PTN in dopamine neurons.

case closed: nothing better to follow up.

receipt 6645: PTN in oligodendrocytes, braak

power: full sample -0.15 (p 0.549, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.20 (p 0.418, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.13 (p 0.597, n 18). could be the mix.
skeptic: leave-one-out range -0.28 to -0.02, sign flips 0; without severely affected donors -0.15 (p 0.549, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PTN in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts